110 related articles for article (PubMed ID: 8788494)
21. Mixed agonist/antagonist properties of NAN-190 at 5-HT1A receptors: behavioural and in vivo brain microdialysis studies.
Hjorth S; Sharp T
Life Sci; 1990; 46(13):955-63. PubMed ID: 2329921
[TBL] [Abstract][Full Text] [Related]
22. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.
Millan MJ; Hjorth S; Samanin R; Schreiber R; Jaffard R; De Ladonchamps B; Veiga S; Goument B; Peglion JL; Spedding M; Brocco M
J Pharmacol Exp Ther; 1997 Jul; 282(1):148-61. PubMed ID: 9223550
[TBL] [Abstract][Full Text] [Related]
23. Two selective 5-HT1A receptor antagonists, WAY-100 635 and NDL-249, stimulate locomotion in rats acclimatised to their environment and alter their behaviour: a behavioural analysis.
Jackson DM; Wallsten CE; Jerning E; Hu PS; Deveney AM
Psychopharmacology (Berl); 1998 Oct; 139(4):300-10. PubMed ID: 9809851
[TBL] [Abstract][Full Text] [Related]
24. Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdialysis studies in the awake and anaesthetized rat.
Done CJ; Sharp T
Neuropharmacology; 1994; 33(3-4):411-21. PubMed ID: 7984279
[TBL] [Abstract][Full Text] [Related]
25. The putative 5-HT1A receptor antagonist DU125530 blocks the discriminative stimulus of the 5-HT1A receptor agonist flesinoxan in pigeons.
Mos J; Van Hest A; Van Drimmelen M; Herremans AH; Olivier B
Eur J Pharmacol; 1997 May; 325(2-3):145-53. PubMed ID: 9163561
[TBL] [Abstract][Full Text] [Related]
26. Effects of sustained (+/-)pindolol administration on serotonin neurotransmission in rats.
Haddjeri N; Blier P
J Psychiatry Neurosci; 2000 Sep; 25(4):378-88. PubMed ID: 11022403
[TBL] [Abstract][Full Text] [Related]
27. Involvement of 5-HT1A receptors in the anxiolytic action of S 14671 in the pigeon conflict test.
Schreiber R; Brocco M; de Ladonchamps BL; Millan MJ
Pharmacol Biochem Behav; 1995; 51(2-3):211-5. PubMed ID: 7667330
[TBL] [Abstract][Full Text] [Related]
28. Anxiolytic 5-hydroxytryptamine1A agonists suppress firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: single-unit study in unanesthetized, unrestrained rats.
Tada K; Kasamo K; Ueda N; Suzuki T; Kojima T; Ishikawa K
J Pharmacol Exp Ther; 1999 Feb; 288(2):843-8. PubMed ID: 9918598
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological analysis of the hypothermic effects of NAN-190 and its analogs, postsynaptic 5-HT1A receptor antagonists, in mice.
Wesołowska A; Borycz J; Paluchowska MH; Chojnacka-Wójcik E
Pol J Pharmacol; 2002; 54(4):391-9. PubMed ID: 12523493
[TBL] [Abstract][Full Text] [Related]
30. 5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential.
Koek W; Vacher B; Cosi C; Assié MB; Patoiseau JF; Pauwels PJ; Colpaert FC
Eur J Pharmacol; 2001 May; 420(2-3):103-12. PubMed ID: 11408031
[TBL] [Abstract][Full Text] [Related]
31. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535.
Lejeune F; Millan MJ
Synapse; 1998 Oct; 30(2):172-80. PubMed ID: 9723787
[TBL] [Abstract][Full Text] [Related]
32. Estimation of apparent pA2 values for WAY 100635 at 5-HT1A receptors regulating 5-hydroxytryptamine release in anaesthetised rats.
Assié MB; Koek W
Eur J Pharmacol; 2000 Dec; 409(2):173-7. PubMed ID: 11104831
[TBL] [Abstract][Full Text] [Related]
33. Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy.
Newman-Tancredi A; Conte C; Chaput C; Verrièle L; Audinot-Bouchez V; Lochon S; Lavielle G; Millan MJ
Naunyn Schmiedebergs Arch Pharmacol; 1997 Jun; 355(6):682-8. PubMed ID: 9205951
[TBL] [Abstract][Full Text] [Related]
34. 5-HT1A receptor full and partial agonists and 5-HT2C (but not 5-HT3) receptor antagonists increase rates of punished responding in rats.
Cervo L; Samanin R
Pharmacol Biochem Behav; 1995 Dec; 52(4):671-6. PubMed ID: 8587903
[TBL] [Abstract][Full Text] [Related]
35. Comparative effects of novel 5-HT1A receptor ligands, LY293284, LY315712 and LY297996, on plus-maze anxiety in mice.
Cao BJ; Rodgers RJ
Psychopharmacology (Berl); 1998 Oct; 139(3):185-94. PubMed ID: 9784072
[TBL] [Abstract][Full Text] [Related]
36. In vivo electrophysiological assessment of the agonistic properties of flibanserin at pre- and postsynaptic 5-HT1A receptors in the rat brain.
Rueter LE; de Montigny C; Blier P
Synapse; 1998 Aug; 29(4):392-405. PubMed ID: 9661257
[TBL] [Abstract][Full Text] [Related]
37. Some pharmacological properties of new analogs of MP 3022, the 5-HT1A receptor antagonist.
Chojnacka-Wójcik E; Kłodzińska A; Tatarczyńska E; Paluchowska MH
Pol J Pharmacol; 1999; 51(5):405-13. PubMed ID: 10817541
[TBL] [Abstract][Full Text] [Related]
38. Effect of acute administration of the 5-HT1A receptor ligand, lesopitron, on rat cortical 5-HT and dopamine turnover.
Ballarín M; Carceller A; Guitart X
Br J Pharmacol; 1994 Oct; 113(2):425-30. PubMed ID: 7530571
[TBL] [Abstract][Full Text] [Related]
39. Pharmacology of 5-hydroxytryptamine-1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture.
Dumuis A; Sebben M; Bockaert J
Mol Pharmacol; 1988 Feb; 33(2):178-86. PubMed ID: 2828913
[TBL] [Abstract][Full Text] [Related]
40. Buspirone analogues as ligands of the 5-HT1A receptor. II: Capacity factors as chromatographic parameter of lipophilicity evaluation in a series of 5-HT1A and 5-HT2A receptor ligands.
Chilmonczyk Z; Ksycińska H; Cybulski J; Woźniakowska-Szelejewska A
Pharmazie; 1996 Dec; 51(12):924-7. PubMed ID: 8985981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
